CYP2E1 and metabolic dysfunction-associated steatotic liver disease: Treatment of nonalcoholic fatty liver disease→ Modulation of the hepatic-SREBP-1c- and CYP2E1-mediated pathway↓ Hyperlipidemia↓TG, TC